BERGENBIO AS BRRGF overview

BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation PR Newswire BERGEN, Norway, March 20, 2024 BerGenBio receives positive recommendation from independent Data and Safety Monitoring Board to proceed without study modification BERGEN, Norway , March 20, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today...

BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections PR Newswire BERGEN, Norway, Feb. 7, 2024 BERGEN, Norway , Feb. 7, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Dr. Mirella Spalluto of the University of Southampton today presented "Investigating the effects of AXL...

BerGenBio Reports Third Quarter 2023 Financial Results PR Newswire BERGEN, Norway, Nov. 14, 2023 BERGEN, Norway , Nov. 14, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter ended September 30, 2023 , and provided a business update. "We are pleased to report continued advancement of our focused strategy to study our lead...

BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC PR Newswire BERGEN, Norway, Nov. 6, 2023 Presented at 2023 SITC Meeting - A pre-planned biomarker analysis of patients treated with bemcentinib in combination with KEYTRUDA ® (pembrolizumab) yields new understandings- BERGEN, Norway , Nov. 6, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced that a...

BerGenBio Announces Poster Presentation at Upcoming SITC Meeting PR Newswire BERGEN, Norway, Oct. 31, 2023 BERGEN, Norway , Oct. 31, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster highlighting data from pre-planned biomarker analyses in second line Non-Small Cell Lung Cancer (NSCLC) patients treated with bemcentinib, a highly selective AXL...

New Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting PR Newswire BERGEN, Norway, Oct. 23, 2023 BERGEN, Norway , Oct. 23, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that the full results of its Phase 2 BGBC008 study of bemcentinib and pembrolizumab in second line Non-Small Cell Lung Cancer (NSCLC) were...

Additional data on BerGenBio's selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting PR Newswire BERGEN, Norway, Oct. 16, 2023 BERGEN, Norway , Oct. 16, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at...

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer PR Newswire BERGEN, Norway, Aug. 22, 2023 BERGEN, Norway , Aug. 22, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that additional clinical data of bemcentinib in combination with chemotherapy and with...